Treatment of Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma with Two Ifosfamide-Based Regimens, IMVP and ICE

Authors: Aurer, I.; Mitrović, Z.; Nemet, D.; Radman, I.; Sertić, D.; Serventi-Seiwerth, R.; Štern-Padovan, R.; Šantek, F.; Nola, M.; Mrsić, M.; Labar, B.

Source: Journal of Chemotherapy, Number 5, October 2008 , pp. 640-644(5)

Publisher: Maney Publishing

Buy & download fulltext article:

Price: $48.00 plus tax (Refund Policy)

Abstract:

We report the outcomes of 45 patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) treated with a combination of ifosfamide, carboplatinum and etoposide (ICE) and 28 patients treated with a combination of ifosfamide, methotrexate and etoposide (IMVP) during two 5-year periods. The response rate (RR) to ICE was 47%, 2-year overall survival (OS) 31% and 2-year event-free survival (EFS) 22%. These results were similar to those obtained with IMVP (RR 39%, 2-year OS 23%, 2-year EFS 13%; p=0.355 for RR, 0.275 for OS, 0.668 for EFS). Higher IPI scores and refractoriness to treatment were negative prognostic factors, immunophenotype (B vs. T) had no influence on prognosis. Changing from IMVP to ICE does not substantially improve the outcome of patients with relapsed or refractory aggressive NHL. Patients with relapsed/refractory aggressive B-NHL do not have a superior out-come in comparison to those with T-NHL if treated with chemotherapy alone.

Keywords: lymphoma diffuse; lymphoma T-cell; ifosfamide; lym-phoma large-cell; lymphoma B-cell; methotrexate; Lymphoma non-Hodgkin; carboplatinum; etoposide

Document Type: Research Article

Publication date: 2008-10-01

More about this publication?